Skip to main content
Top
Published in: Inflammation 1/2013

01-02-2013

Inflammatory Processes and Effects of Continuous Positive Airway Pressure (CPAP) in Overlap Syndrome

Authors: Serkan Nural, Ersin Günay, Bilal Halici, Sefa Celik, Mehmet Ünlü

Published in: Inflammation | Issue 1/2013

Login to get access

Abstract

We aimed to compare serum levels of the inflammatory mediators including C-reactive protein (CRP), tumor necrosis factor-α (TNF-α), and asymmetric dimethylarginine (ADMA) in chronic obstructive pulmonary disease (COPD), obstructive sleep apnea syndrome (OSAS), and their coexistence called overlap syndrome (OVS). In addition, we planned to investigate changes of these mediators with the treatment of continuous positive airway pressure (CPAP) in OSAS and OVS. CRP, TNF-α, and ADMA levels were analyzed by ELISA method from blood samples withdrawn from patients with COPD (N = 25), OVS (N = 25), and moderate- to severe-stage OSAS (N = 25). First blood samples were taken in the morning after polysomnography application, and second blood samples were taken from OSAS and OVS patients who underwent regular CPAP treatment. In comparison of three groups prior to CPAP treatment, ADMA level in OSAS were significantly lower than in COPD (p = 0.009), but CRP and TNF-α were similar among groups. When we compared the parameters before and after CPAP treatment, the level of CRP in both OSAS and OVS decreased significantly (p = 0.02, p = 0.04), whereas TNF-α and ADMA levels did not display any significant differences. A decrease of serum CRP level in OVS and OSAS groups following effective CPAP treatment shows that CPAP is an effective treatment method for systemic inflammation.
Literature
2.
go back to reference Lurie, A. 2011. Obstructive sleep apnea in adults: epidemiology, clinical presentation, and treatment options. Advances in Cardiology 46: 1–42.PubMedCrossRef Lurie, A. 2011. Obstructive sleep apnea in adults: epidemiology, clinical presentation, and treatment options. Advances in Cardiology 46: 1–42.PubMedCrossRef
3.
go back to reference Kanbay, A., E. Kaya, H. Buyukoglan, N. Ozdogan, M.G. Kaya, F.S. Oymak, I. Gulmez, R. Demir, and O. Kokturk. 2011. Serum gamma-glutamyl transferase activity is an independent predictor for cardiovascular disease in obstructive sleep apnea syndrome. Respiratory Medicine 105: 637–642.PubMedCrossRef Kanbay, A., E. Kaya, H. Buyukoglan, N. Ozdogan, M.G. Kaya, F.S. Oymak, I. Gulmez, R. Demir, and O. Kokturk. 2011. Serum gamma-glutamyl transferase activity is an independent predictor for cardiovascular disease in obstructive sleep apnea syndrome. Respiratory Medicine 105: 637–642.PubMedCrossRef
4.
go back to reference Fava, C., M. Montagnana, E.J. Favaloro, G.C. Guidi, and G. Lippi. 2011. Obstructive sleep apnea syndrome and cardiovascular diseases. Seminars in Thrombosis and Hemostasis 37: 280–297.PubMedCrossRef Fava, C., M. Montagnana, E.J. Favaloro, G.C. Guidi, and G. Lippi. 2011. Obstructive sleep apnea syndrome and cardiovascular diseases. Seminars in Thrombosis and Hemostasis 37: 280–297.PubMedCrossRef
5.
go back to reference McNicholas, W.T. 2009. Chronic obstructive pulmonary disease and obstructive sleep apnea: overlaps in pathophysiology, systemic inflammation, and cardiovascular disease. American Journal of Respiratory and Critical Care Medicine 180(8): 692–700.PubMedCrossRef McNicholas, W.T. 2009. Chronic obstructive pulmonary disease and obstructive sleep apnea: overlaps in pathophysiology, systemic inflammation, and cardiovascular disease. American Journal of Respiratory and Critical Care Medicine 180(8): 692–700.PubMedCrossRef
6.
go back to reference Gozal, D., and L. Kheirandish-Gozal. 2008. Cardiovascular morbidity in obstructive sleep apnea: oxidative stress, inflammation, and much more. American Journal of Respiratory and Critical Care Medicine 177: 369–375.PubMedCrossRef Gozal, D., and L. Kheirandish-Gozal. 2008. Cardiovascular morbidity in obstructive sleep apnea: oxidative stress, inflammation, and much more. American Journal of Respiratory and Critical Care Medicine 177: 369–375.PubMedCrossRef
7.
go back to reference Sin, D.D., and S.F.P. Man. 2005. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proceedings of the American Thoracic Society 2: 8–11.PubMedCrossRef Sin, D.D., and S.F.P. Man. 2005. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proceedings of the American Thoracic Society 2: 8–11.PubMedCrossRef
8.
go back to reference Iber, C., Ancoli-Israel, S., Chesson, A., Quan, S.F., editors. 1st ed. Westchester, IL: American Academy of sleep medicine; 2007. The AASM manual for the scoring of sleep and associated events: rules, terminology, and technical specification. Iber, C., Ancoli-Israel, S., Chesson, A., Quan, S.F., editors. 1st ed. Westchester, IL: American Academy of sleep medicine; 2007. The AASM manual for the scoring of sleep and associated events: rules, terminology, and technical specification.
9.
go back to reference Karadag, F., S. Kirdar, A.B. Karul, and E. Ceylan. 2008. The value of C-reactive protein as a marker of systemic inflammation in stable chronic obstructive pulmonary disease. European Journal of Internal Medicine 19: 104–108.PubMedCrossRef Karadag, F., S. Kirdar, A.B. Karul, and E. Ceylan. 2008. The value of C-reactive protein as a marker of systemic inflammation in stable chronic obstructive pulmonary disease. European Journal of Internal Medicine 19: 104–108.PubMedCrossRef
10.
go back to reference Wang, S., F. Xu, and Y. Chen. 2000. Detection and significance of IL-8, 6, TNF-alpha in sputa from patients with COPD. Zhonghua Jie He He Hu Xi Za Zhi 23: 465–467.PubMed Wang, S., F. Xu, and Y. Chen. 2000. Detection and significance of IL-8, 6, TNF-alpha in sputa from patients with COPD. Zhonghua Jie He He Hu Xi Za Zhi 23: 465–467.PubMed
11.
go back to reference Gan, W.Q., S.F. Man, A. Senthilselvan, and D.D. Sin. 2004. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 59: 574–580.PubMedCrossRef Gan, W.Q., S.F. Man, A. Senthilselvan, and D.D. Sin. 2004. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 59: 574–580.PubMedCrossRef
12.
go back to reference Stankiewicz, W., M.P. Dabrowski, A. Chcialowski, and T. Plusa. 2002. Cellular and cytokine immunoregulation in patients with chronic obstructive pulmonary disease and bronchial asthma. Mediators of Inflammation 11: 307–312.PubMedCrossRef Stankiewicz, W., M.P. Dabrowski, A. Chcialowski, and T. Plusa. 2002. Cellular and cytokine immunoregulation in patients with chronic obstructive pulmonary disease and bronchial asthma. Mediators of Inflammation 11: 307–312.PubMedCrossRef
13.
go back to reference Vernooy, J.H., M. Kucukaycan, J.A. Jacobs, N.H. Chavannes, W.A. Buurman, M.A. Dentener, and E.F. Wouters. 2002. Local and systemic inflammation in patients with COPD: soluble tumor necrosis factor receptors are increased in sputum. American Journal of Respiratory and Critical Care Medicine 166: 1218–1224.PubMedCrossRef Vernooy, J.H., M. Kucukaycan, J.A. Jacobs, N.H. Chavannes, W.A. Buurman, M.A. Dentener, and E.F. Wouters. 2002. Local and systemic inflammation in patients with COPD: soluble tumor necrosis factor receptors are increased in sputum. American Journal of Respiratory and Critical Care Medicine 166: 1218–1224.PubMedCrossRef
14.
go back to reference Yokoe, T., K. Minoguchi, H. Matsuo, H. Minoguchi, G. Yoshino, T. Hirano, and M. Adachi. 2003. Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. Circulation 107: 1129–1134.PubMedCrossRef Yokoe, T., K. Minoguchi, H. Matsuo, H. Minoguchi, G. Yoshino, T. Hirano, and M. Adachi. 2003. Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. Circulation 107: 1129–1134.PubMedCrossRef
15.
go back to reference Shamsuzzaman, A.S., M. Winnicki, P. Lanfranchi, R. Wolk, T. Kara, V. Accurso, and V.K. Somers. 2002. Elevated C-reactive protein in patients with obstructive sleep apnea. Circulation 105: 2462–2464.PubMedCrossRef Shamsuzzaman, A.S., M. Winnicki, P. Lanfranchi, R. Wolk, T. Kara, V. Accurso, and V.K. Somers. 2002. Elevated C-reactive protein in patients with obstructive sleep apnea. Circulation 105: 2462–2464.PubMedCrossRef
16.
go back to reference Can, M., S. Açikgöz, G. Mungan, T. Bayraktaroğlu, E. Koçak, B. Güven, and S. Demirtas. 2006. Serum cardiovascular risk factors in obstructive sleep apnea. Chest 129: 233–237.PubMedCrossRef Can, M., S. Açikgöz, G. Mungan, T. Bayraktaroğlu, E. Koçak, B. Güven, and S. Demirtas. 2006. Serum cardiovascular risk factors in obstructive sleep apnea. Chest 129: 233–237.PubMedCrossRef
17.
go back to reference Firat Guven, S., M.H. Turkkani, B. Ciftci, T. Ulukavak Ciftci, and Y. Erdogan. 2012. The relationship between high-sensitivity C-reactive protein levels and the severity of obstructive sleep apnea. Sleep & Breathing 16: 217–221.CrossRef Firat Guven, S., M.H. Turkkani, B. Ciftci, T. Ulukavak Ciftci, and Y. Erdogan. 2012. The relationship between high-sensitivity C-reactive protein levels and the severity of obstructive sleep apnea. Sleep & Breathing 16: 217–221.CrossRef
18.
go back to reference Boudjeltia, K.Z., A.V. Meerhaeghe, S. Doumit, M. Guillaume, P. Cauchie, D. Brohée, M. Vanhaeverbeek, and M. Kerkhofs. 2006. Sleep apnoea–hypopnoea index is an independent predictor of high-sensitivity C-reactive protein elevation. Respiration 73: 243–246.CrossRef Boudjeltia, K.Z., A.V. Meerhaeghe, S. Doumit, M. Guillaume, P. Cauchie, D. Brohée, M. Vanhaeverbeek, and M. Kerkhofs. 2006. Sleep apnoea–hypopnoea index is an independent predictor of high-sensitivity C-reactive protein elevation. Respiration 73: 243–246.CrossRef
19.
go back to reference Teramoto, S., H. Yamamoto, and Y. Ouchi. 2003. Increased C-reactive protein and increased plasma interleukin-6 may synergistically affect the progression of coronary atherosclerosis in obstructive sleep apnea syndrome. Circulation 107: 40–43.CrossRef Teramoto, S., H. Yamamoto, and Y. Ouchi. 2003. Increased C-reactive protein and increased plasma interleukin-6 may synergistically affect the progression of coronary atherosclerosis in obstructive sleep apnea syndrome. Circulation 107: 40–43.CrossRef
20.
go back to reference Kanbay, A., O. Kokturk, T. Ulukavak Ciftci, Y. Tavil, and N. Bukan. 2008. Comparison of serum adiponectin and tumor necrosis factor-alpha levels between patients with and without obstructive apnea syndrome. Respiration 76: 324–330.PubMedCrossRef Kanbay, A., O. Kokturk, T. Ulukavak Ciftci, Y. Tavil, and N. Bukan. 2008. Comparison of serum adiponectin and tumor necrosis factor-alpha levels between patients with and without obstructive apnea syndrome. Respiration 76: 324–330.PubMedCrossRef
21.
go back to reference Nijveldt, R.J., T. Teerlink, C. van Guldener, H.A. Prins, A.A. van Lambalgen, C.D. Stehouwer, J.A. Rauwerda, and P.A. van Leeuwen. 2003. Handling of asymmetrical dimethylarginine and symmetrical dimethylarginine by the rat kidney under basal conditions and during endotoxaemia. Nephrology, Dialysis, Transplantation 18: 2542–2550.PubMedCrossRef Nijveldt, R.J., T. Teerlink, C. van Guldener, H.A. Prins, A.A. van Lambalgen, C.D. Stehouwer, J.A. Rauwerda, and P.A. van Leeuwen. 2003. Handling of asymmetrical dimethylarginine and symmetrical dimethylarginine by the rat kidney under basal conditions and during endotoxaemia. Nephrology, Dialysis, Transplantation 18: 2542–2550.PubMedCrossRef
22.
go back to reference Abbasi, F., T. Asagmi, J.P. Cooke, C. Lamendola, T. McLaughlin, G.M. Reaven, M. Stuehlinger, and P.S. Tsao. 2001. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. The American Journal of Cardiology 88: 1201–1203.PubMedCrossRef Abbasi, F., T. Asagmi, J.P. Cooke, C. Lamendola, T. McLaughlin, G.M. Reaven, M. Stuehlinger, and P.S. Tsao. 2001. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. The American Journal of Cardiology 88: 1201–1203.PubMedCrossRef
23.
go back to reference Millatt, L.J., G.S. Whitley, D. Li, J.M. Leiper, H.M. Siragy, R.M. Carey, and R.A. Johns. 2003. Evidence for dysregulation of dimethylarginine dimethylaminohydrolase I in chronic hypoxia-induced pulmonary hypertension. Circulation 108: 1493–1498.PubMedCrossRef Millatt, L.J., G.S. Whitley, D. Li, J.M. Leiper, H.M. Siragy, R.M. Carey, and R.A. Johns. 2003. Evidence for dysregulation of dimethylarginine dimethylaminohydrolase I in chronic hypoxia-induced pulmonary hypertension. Circulation 108: 1493–1498.PubMedCrossRef
24.
go back to reference Chen, G.F., N.C. Moningka, J.M. Sasser, S. Zharikov, M. Cunningham Jr., Y.L. Tain, I.F. Schwartz, and C. Baylis. 2012. Arginine and asymmetric dimethylarginine in puromycin aminonucleoside-ınduced chronic kidney disease in the rat. American Journal of Nephrology 35: 40–48.PubMedCrossRef Chen, G.F., N.C. Moningka, J.M. Sasser, S. Zharikov, M. Cunningham Jr., Y.L. Tain, I.F. Schwartz, and C. Baylis. 2012. Arginine and asymmetric dimethylarginine in puromycin aminonucleoside-ınduced chronic kidney disease in the rat. American Journal of Nephrology 35: 40–48.PubMedCrossRef
25.
go back to reference Barceló, A., M. de la Peña, O. Ayllón, M.V. Vega-Agapito, J. Piérola, G. Pérez, C. González, A. Alonso, and A.G. Agustí. 2009. Increased plasma levels of asymmetric dimethylarginine and soluble CD40 ligand in patients with sleep apnea. Respiration 77: 85–90.PubMedCrossRef Barceló, A., M. de la Peña, O. Ayllón, M.V. Vega-Agapito, J. Piérola, G. Pérez, C. González, A. Alonso, and A.G. Agustí. 2009. Increased plasma levels of asymmetric dimethylarginine and soluble CD40 ligand in patients with sleep apnea. Respiration 77: 85–90.PubMedCrossRef
26.
go back to reference Ozkan, Y., H. Firat, B. Simşek, M. Torun, and S. Yardim-Akaydin. 2008. Circulating nitric oxide (NO), asymmetric dimethylarginine (ADMA), homocysteine, and oxidative status in obstructive sleep apnea-hypopnea syndrome (OSAHS). Sleep & Breathing 12: 149–154.CrossRef Ozkan, Y., H. Firat, B. Simşek, M. Torun, and S. Yardim-Akaydin. 2008. Circulating nitric oxide (NO), asymmetric dimethylarginine (ADMA), homocysteine, and oxidative status in obstructive sleep apnea-hypopnea syndrome (OSAHS). Sleep & Breathing 12: 149–154.CrossRef
27.
go back to reference Kohler, M., L. Ayers, J.C.T. Pepperell, K.L. Packwood, B. Ferry, N. Crosthwaite, S. Craig, M.M. Siccoli, R.J. Davies, and J.R. Stradling. 2009. Effects of continuous positive airway pressure on systemic inflammation in patients with moderate to severe obstructive sleep apnoea: a randomised controlled trial. Thorax 64(1): 67–73.PubMedCrossRef Kohler, M., L. Ayers, J.C.T. Pepperell, K.L. Packwood, B. Ferry, N. Crosthwaite, S. Craig, M.M. Siccoli, R.J. Davies, and J.R. Stradling. 2009. Effects of continuous positive airway pressure on systemic inflammation in patients with moderate to severe obstructive sleep apnoea: a randomised controlled trial. Thorax 64(1): 67–73.PubMedCrossRef
28.
go back to reference Steiropoulos, P., I. Kotsianidis, E. Nena, V. Tsara, E. Gounari, O. Hatzizisi, G. Kyriazis, P. Christaki, M. Froudarakis, and D. Bouros. 2009. Long-term effect of continuous positive airway pressure therapy on inflammation markers of patients with obstructive sleep apnea syndrome. Sleep 32: 537–543.PubMed Steiropoulos, P., I. Kotsianidis, E. Nena, V. Tsara, E. Gounari, O. Hatzizisi, G. Kyriazis, P. Christaki, M. Froudarakis, and D. Bouros. 2009. Long-term effect of continuous positive airway pressure therapy on inflammation markers of patients with obstructive sleep apnea syndrome. Sleep 32: 537–543.PubMed
29.
go back to reference Ohike, Y., K. Kozaki, K. Iijima, M. Eto, T. Kojima, E. Ohga, T. Santa, K. Imai, M. Hashimoto, M. Yoshizumi, and Y. Ouchi. 2005. Amelioration of vascular endothelial dysfunction in obstructive sleep apnea syndrome by nasal continuous positive airway pressure—possible involvement of nitric oxide and asymmetric NG, NG-dimethylarginine. Circulation Journal 69: 221–226.PubMedCrossRef Ohike, Y., K. Kozaki, K. Iijima, M. Eto, T. Kojima, E. Ohga, T. Santa, K. Imai, M. Hashimoto, M. Yoshizumi, and Y. Ouchi. 2005. Amelioration of vascular endothelial dysfunction in obstructive sleep apnea syndrome by nasal continuous positive airway pressure—possible involvement of nitric oxide and asymmetric NG, NG-dimethylarginine. Circulation Journal 69: 221–226.PubMedCrossRef
30.
go back to reference Mansour, H.A.K.A., A. Fathy, and H. Aref. 2011. Effect of nasal continuous positive airway pressure on inflammatory mediators in patients with overlap syndrome. Egyptian Journal of Ear, Nose, Throat and Allied Sciences 12: 99–104.CrossRef Mansour, H.A.K.A., A. Fathy, and H. Aref. 2011. Effect of nasal continuous positive airway pressure on inflammatory mediators in patients with overlap syndrome. Egyptian Journal of Ear, Nose, Throat and Allied Sciences 12: 99–104.CrossRef
Metadata
Title
Inflammatory Processes and Effects of Continuous Positive Airway Pressure (CPAP) in Overlap Syndrome
Authors
Serkan Nural
Ersin Günay
Bilal Halici
Sefa Celik
Mehmet Ünlü
Publication date
01-02-2013
Publisher
Springer US
Published in
Inflammation / Issue 1/2013
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-012-9520-z

Other articles of this Issue 1/2013

Inflammation 1/2013 Go to the issue